Figures computed from official regulatory filings — .
Analysttarget 27.57 USD (+152%) · consensus 4.87/5 · 15 buy · 0 hold · 0 sell
Ownershipinsiders 0.18% · institutions 105.43% · short 20.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Climb Bio, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
8 buys27 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, LLCtrack record | Exercise | $30K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Exercise | $51.6K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Exercise | $78.9K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Exercise | $34.6K | SEC |
| Thomas Stephen Basil | Sell | $1.4M | Unusual size | SEC |
| Celebi Breanna Maurine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brennan Aoife | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Brennan Aoife | Sell | $407K | Unusual size | SEC |
| Brennan Aoife | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dunn Judith | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Levin Andrew David | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Drapkin Kimberlee C | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thomas Stephen Basil | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WILLIAMS DOUGLAS Etrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cumbo Alexander | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | AwardD (derivative) | $20M | SEC |
| Thomas Stephen Basil | Sell | $235.8K | SEC |
| Thomas Stephen Basil | Sell | $114.4K | SEC |
| Thomas Stephen Basil | Sell | $470.7K | SEC |